Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC)

  • Etude concernée: GCO-001
  • Auteurs / Authors: N. Girard, J. Mazieres, J. Otto, H. Lena, C. Lepage, T. Egenod, D. Smith, J. Madelaine, L. Gérinière, F. El Hajbi, A. Ferru, C. Clément-Duchêne, A. Madroszyk, J. Desrame, F. Morin, A. Langlais, P. Michel, C. Louvet, V. Westeel, T. Walter
  • Journal / Conference: ESMO
  • Année / Year: 2021
  • PMID: Proffered Paper session
  • Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/nivolumab-nivo-ipilimumab-ipi-in-pre-treated-patients-with-advanced-refractory-pulmonary-or-gastroenteropancreatic-poorly-differentiated-neu